Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

AIMS: Interindividual differences in the pharmacokinetics of venlafaxine, a new antidepressant, were shown during early clinical trials in Japan. Venlafaxine is metabolized mainly by CYP2D6 to an active metabolite, O-desmethylvenlafaxine (ODV). Therefore, the influence of the CYP2D6 genotypes on ven...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Fukuda, Tsuyoshi, Yamamoto, Isamu, Nishida, Yuko, Zhou, Qian, Ohno, Masako, Takada, Kanji, Azuma, Junichi
Formato: Artigo
Idioma:Inglês
Publicado: Blackwell Science Inc 1999
Assuntos:
Short Reports
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2014246/
https://ncbi.nlm.nih.gov/pubmed/10233212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.1999.00913.x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares